Pb2432 possible Genetic Risk Factors of Pulmonary Embolism in Young Patients From the North‐western Region of Russia

Abstract

equal to 3) of 53.5%. The mean creatinine clearance value was 118.48 ml/min and the mean follow-up of these patients was 13.57 months. Results: : It has not been reported any case of Stroke, Systemic Embolism, or Major Bleeding (according to the criteria of the ISTH) during the follow-up time of the patients treated, both in the main group and in the subpopulation of patients with creatinine clearance above 95 ml/min. Only 3% of patients (17) had complications with Edoxaban, of which 12 had discontinued treatment for this cause. No case of severe or clinically relevant major bleeding has been reported according to the ISTH criteria. During the time of follow-up, twelve cases of death occurred from their base disease or from other causes, but in no case related to Edoxaban. Summary/Conclusion: This is a good sample of 552 patients and more than with a mean of 13 months of follow-up. In the analyzed subpopulation of patients with creatinine clearance greater than 95 ml/min, the good results of Edoxaban are confirmed since they have not presented any stroke recurrence or systemic embolism or major or clinically relevant hemorrhage according to the ISTH criteria. Due to the sample of 127 patients, more studies will be needed to confirm this assertion.